Biovitrum AB Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Stockholm Sweden (2001)
Status: Acquired by Swedish Orphan Biovitrum (2010) → now Advent International (2021)

Organization Overview

First Clinical Trial
2005
NCT00361348
First Marketed Drug
2001
anakinra (Kineret)
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BIOVITRUM AB | Biovitrum AB (publ)

Active Ingredients

Marketed Drugs (2)

anakinra (Kineret) (2001)

palifermin (Kepivance) (2004)

Drugs in Phase 4 Trials (1)

palifermin (Kepivance) (3 trials)

Drugs in Phase 2 Trials (1)

bile-salt-stimulated lipase (2 trials)

Drugs in Phase 1 Trials (1)

heparin (liquaemin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Head and Neck Neoplasms (Phase 2)

Lymphoma (Phase 4)

Lymphoma, Non-Hodgkin (Phase 4)

Mucositis (Phase 4)

Multiple Myeloma (Phase 4)

Neoplasms, Plasma Cell (Phase 4)

Premature Birth (Phase 2)

Stomatitis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 3